In response to the MCC audit review, WPBTS has voluntarily ceased production of its PDMP’s and has permanently closed the Pharmaceutical Division after thirty years in operation.
WPBTS and SANBS are evaluating/reviewing the feasibility of pathogen reduction technology for pooled random donor platelets and single donor apheresis platelets for implementation in South Africa.
WPBTS and SANBS’s reporting of adverse blood transfusion/donation events in South Africa is available in the latest SA National Haemovigilance Report (2014), on the haemovigilance information page.
WPBTS is conducting its annual customer satisfaction survey for blood users. To participate in the survey visit the Life Blood Newsletter Edition 26, on the latest news page.
